Clinical Trial Search

Primary: Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population — 26.4; 3.6 L/min — p=<0.001

Primary: Asthma Control — 312; 72; 0; 229 Participants

Primary: Asthma Control Test (ACT) — 2.95; 2.44 units on a scale

Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049

Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale

Primary: The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment. — 25.3; 26.7; -10.3; 0.4 units on a scale — p=0.001

Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…

Primary: Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS) — 6.5; 5.9; -0.9; -1.4 Score on a scale — p=0.101

Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants

Primary: Change From Baseline for Daytime Asthma Symptom Score — 0.32; 0.16; 0.29; 0.13 Units on scale — p=0.015

Primary: Tidal Nitric Oxide — 18.7 ppb

Primary: Characterize Contribution of Histamine in Children With Asthma — 11253.24; 6464.20; 3539.67 flux units on a continuous scale

Primary: Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection. — 4.0; 3.3 units on a scale — p=0.59

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale

Primary: Change in Exhaled Nitric Oxide From Baseline to Week 12 — -11.0 parts per billion (ppb) — p=0.005

Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score

Primary: Total Lower Respiratory Symptom Score — 21; 18 score on a scale — p=0.78

Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38

Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period — -0.23; -0.33; -0.45 Scores on a scale

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.26; -0.48; -0.52; -0.58 Units on a Scale

Primary: FEV1, Late Asthmatic Response (LAR) - Pre-treatment — 0.814; 1.01 ratio

Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032

Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change

Primary: Daily Symptom Load — 1.25; 1.10; 1.32; 0.97 units on a scale

Primary: Change From Baseline in Fatigue and Daytime Sleepiness at 2 Weeks — -0.64; 0.13; 0.46; -0.25 units on a scale

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period — -0.38; -0.47; -0.29 Scores on a scale

Primary: Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum Forced Expiratory Volume in 1 Second (FEV1) Between 4-10 Hours Following Allergen Challenge One…

Primary: Change From Baseline at Week 16 in Sinonasal Outcome Test -22 (SNOT-22) Score — -14.09; -4.37 points